scholarly journals A corneal surface study in patients after laser keratomilesis

2013 ◽  
Vol 6 (3) ◽  
pp. 32-36
Author(s):  
Vyacheslav Igorevich Maslennikov ◽  
Sergey Alekseyevich Koskin ◽  
Yuriy Yevgenyevich Shelepin ◽  
Aleksandr Vladimirovich Yan

The cornea of the human eye is not only refracts the light, but also acts as a convex mirror, which reflects the surroundings. In ophthalmology, an image reflected by its anterior surface is known as the 1st Purkinje image. Characteristics of this image are determined by the properties of the light source and the state of corneal surface. At the present time, there are many methods in ophthalmology to study various properties of the cornea, but most of them either require expensive equipment or are qualitative and not informative. Meanwhile, a “shining” characteristic of the cornea in general is assessed subjectively and is not properly addressed in the ophthalmic literature. Our work was conducted to study the possibility of applying the method of measuring the reflective ability of the cornea to measure the state of its anterior surface. Our study involved men and women aged 18–45 years after laser-assisted in situ keratomilesis (LASIK). With our new method of measuring the corneal reflectance, we investigated patients before surgery, day 1 post-op and after 1 week. Each study case included a measurement of the reflectivity of the cornea after blinking, and after 15 sec. We found that on the day 1 after surgery corneal reflectivity increases, at the same time, 15 sec after blinking it is reduced to normal. This suggests a reduction of the tear film stability and that the patients had some symptoms of corneal syndrome, and as a consequence, increased tear production. One week after surgery, we observed a different picture: the reflective power of the cornea decreased. We consider this to be a sign of corneal nerves damage and decreased tear production.

2019 ◽  
Vol 42 (5) ◽  
pp. 520-525 ◽  
Author(s):  
Maria Serramito ◽  
Ana Privado-Aroco ◽  
Laura Batres ◽  
Gonzalo Carracedo G

2020 ◽  
Vol 17 (3) ◽  
pp. 481-489
Author(s):  
V. V. Brzheskiy ◽  
S. Yu. Golubev ◽  
O. I. Lebedev ◽  
E. S. Milyudin ◽  
A. S. Apostolova ◽  
...  

The purpose: to evaluate the effectiveness of the Delfanto® in the complex therapy of patients with dry eye syndrome of various etiologies and severity of the clinical course.Patients and methods. 114 patients (228 eyes) with dry eye syndrome of various etiologies were examined: 72 patients with chronic meibomian blepharitis and dysfunction of the meibomian glands (xerosis due to increased evaporation of the tear film), 33 women with perimenopause (a mixed form of xerosis with a predominant decrease in the production of components of the tear film) and 9 persons with Syegren syndrome (xerosis due to a pronounced decrease in tear production). All patients received individually selected tear replacement therapy over the past weeks and the drug was not replaced throughout the study. At the same time, patients with mild and moderate clinical course of SSG for 30 days received Delfanto® at a dosage of 60 mg, and with severe course — 120 mg per day.Results. All patients on the background of complex therapy showed a significant decrease in the severity of subjective manifestations of the dry eye syndrome, an increase in the of the tear film stability and indicators of tear production. At the same time, the dynamics of changes in these parameters of the course of the xerotic process increased as the therapy continued, reaching a maximum by the 30th day. The maximum effect of Delfanto® in the complex therapy of patients with dry eye syndrome was observed in patients with chronic meibomian blepharitis. Moreover, patients with a mild clinical course of cornealconjunctival xerosis were the most susceptible to the therapy.Conclusion. The effectiveness of the complex therapy for patients with dry eye syndrome can be significantly increased by prescribing Delfanto® in a daily dose of 60 mg for mild and moderate xerosis and 120 mg — for severe disease. Delfante® can be recommended for widespread clinical use in complex treatment of patients with various clinical and pathogenetic forms of dry eye syndrome. 


2012 ◽  
pp. 1865 ◽  
Author(s):  
Richard Abelson ◽  
Keith Lane ◽  
John Rodriguez ◽  
Patrick Johnston ◽  
Angjeli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document